Core outcome set for metastatic breast cancer (MBC)
A standardized list of outcomes that matter most to patients with metastatic breast cancer, especially related to quality of life, symptoms, and treatment impact. It helps ensure that studies and care focus on what's important to patients.
At a glance
Use when
Conducting clinical trials or observational studies in MBC; designing patient follow-up in clinical practice; developing patient-reported outcome measures; aligning with ICHOM standards
Avoid when
Focusing only on economic evaluation or cost-effectiveness; when only tumor response or survival outcomes are needed; in settings where data collection capacity is very limited
Inputs
Patient-reported outcomes, clinician-reported measures, clinical records, baseline patient characteristics
Outputs
Standardized set of 101 outcomes covering HRQoL, adverse events, clinical data, and patient characteristics
How it works
A Core Outcome Set (COS) for metastatic breast cancer developed through a modified Delphi process involving 141 stakeholders across patient, clinical, industry, and regulatory roles. Finalized by an expert group and accredited by ICHOM, the COS includes 101 variables across health-related quality of life (n=26), adverse events (n=24), baseline patient characteristics (n=9), and clinical variables (n=42). Designed for use in clinical research and practice to standardize outcome measurement.
- Project
- H2O
- Funding
- IMI
- Project status
- Ongoing
- HTA domains
- Clinical Effectiveness, Patient and Social Aspects
- Technology
- Non-specific
- Assumptions
- Outcomes identified reflect international consensus and patient priorities; data can be feasibly collected in research and clinical settings
- Strengths
- Developed with broad international stakeholder involvement including patients; accredited by ICHOM; supports comparability across studies and systems; covers comprehensive domains including psychosocial and functional aspects
- Limitations
- May be resource-intensive to implement fully in routine care; does not include cost or economic outcomes; limited focus on organizational aspects of care
- Geographic & clinical scope
- Metastatic breast cancer (MBC)
- Also known as
- MBC COS, ICHOM Standard Set for Metastatic Breast Cancer
Questions this answers
- › What outcomes should be measured in metastatic breast cancer research?
- › How can quality of life be assessed in MBC patients?
- › What patient-reported outcomes are most important in MBC care?
- › How can we compare results across different MBC studies?
- › What data should be collected in routine care for MBC patients?
- › Which outcomes are endorsed by international consensus for MBC?
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.